Clinical Trial Update: A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Ad-RTS-hIL-12 in combination with Veledimex for glioblastoma and malignant glioma has completed enrollment, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Oligoastrocytoma
• Glioblastoma

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Glioblastoma Multiforme, Anaplastic Oligoastrocytoma | Phase 1 | Status: COMPLETED | Results posted: 2025-04-16